CCR4 Antibody (KW-0761 (Mogamulizumab)) - Chimeric - Azide and BSA Free

Western Blot: CCR4 Antibody (KW-0761 (Mogamulizumab)) - Chimeric [NBP2-81270] - Western Blot using CCR4 Antibody (KW-0761 (Mogamulizumab)) [NBP2-81270]. Human brain cerebellum (A) and human heart (B) lysates (35ug protein in RIPA buffer) were resolved on a 10% SDS PAGE gel and blots probed with the chimeric rabbit IgG version of KW-0761 [NBP2-81270] at 2 ug/ml before detection using an anti-rabbit secondary antibody. A primary incubation of 1h was used and protein was detected by chemiluminescence. The expected running size for CCR4 is 37.7kDa.

• Reactivity: Hu
• Applications: WB, Func
• Clone: KW-0761 (Mogamulizumab)
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: Azide and BSA Free
• Concentration: 1 mg/ml

CCR4 Antibody (KW-0761 (Mogamulizumab)) - Chimeric - Azide and BSA Free Summary

• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: This antibody was prepared by humanization of a mouse anti-CCR4 mAb.
• Specificity: This antibody is specific for human CCR4, a chemokine receptor that is preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes and brain microvascular and coronary artery endothelial cells.
• Isotype: IgG Kappa
• Clonality: Monoclonal
• Host: Rabbit
• Gene: CCR4
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Functional
  • Western Blot
• Application Notes: This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sezary syndrome, and is associated with an overall response rate of 36.8% and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action; in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers.

Packaging, Storage & Formulations

• Storage: Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.
• Buffer: PBS
• Preservative: 0.02% Proclin 300
• Concentration: 1 mg/ml
• Purity: Protein A purified

Alternate Names for CCR4 Antibody (KW-0761 (Mogamulizumab)) - Chimeric - Azide and BSA Free

• C-C chemokine receptor type 4
• C-C CKR-4
• CC-CKR-4HGCN:14099
• CCR4
• CCR-4
• CD194 antigen
• CD194
• chemokine (C-C motif) receptor 4
• chemokine (C-C) receptor 4
• ChemR13
• CKR4MGC88293
• CMKBR4k5-5
• K5-5

Background

Chemokine receptors are G protein-coupled receptors (GPCRs) that play a key role in inflammation and are characterized by similar sequences with a 4 cysteine motif. The C-C receptors are important in the function of T cell chemotaxis and migration of phagocytic cells to sites of inflammation. Receptors for the C-C chemokine family include CCR-1, CCR-2A, CCR-3, CCR-4, CCR-5 and the Duffy blood group antigen.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: CCR4